Liquidia Says Judge Andrews Has Set Aside Injunction Issued In August 2022 In Lawsuit Filed By United Therapeutics, Hence FDA Is No Longer Enjoined From Issuing Final Approval Of Liquidia New Drug Application For Yutrepia (Treprostinil) Inhalation Powder
Portfolio Pulse from Benzinga Newsdesk
Judge Andrews has set aside the injunction issued in August 2022 against Liquidia, allowing the FDA to proceed with the final approval of Liquidia's new drug application for Yutrepia (Treprostinil) Inhalation Powder. The injunction was initially in place due to a lawsuit filed by United Therapeutics.
April 01, 2024 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The decision to set aside the injunction against Liquidia in the lawsuit filed by United Therapeutics may negatively impact United Therapeutics, as it removes a barrier to the approval of a competing drug.
The lifting of the injunction potentially introduces a new competitor to the market for United Therapeutics, which could negatively affect its market share and investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The lifting of the injunction against Liquidia by Judge Andrews is a significant positive development, allowing the FDA to potentially approve its new drug, Yutrepia.
The removal of the legal barrier directly impacts Liquidia's ability to bring Yutrepia to market, likely boosting investor confidence and potentially the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100